NCT05308446 2026-04-13
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
21 trialsNCT05217446 2026-04-07
SEAMARK
Pfizer
Phase 2 Active not recruiting
NCT05041127 2026-02-19
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03944941 2026-02-05
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT04587128 2026-02-05
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT04229459 2026-01-14
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
Rabin Medical Center
Phase 2 Active not recruiting
NCT01025089 2026-01-07
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06578559 2026-01-05
BRICKET
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT02270814 2025-12-30
CACTUX
Washington University School of Medicine
Phase 2 Active not recruiting
NCT01154920 2025-12-17
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05226871 2025-11-25
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Pfizer
Phase 2 Active not recruiting
NCT03493048 2025-08-03
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05312398 2025-05-25
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
University of Campania Luigi Vanvitelli
Phase 2 Active not recruiting
NCT03389477 2025-04-13
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT03646461 2025-04-06
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
University of California, San Diego
Phase 2 Active not recruiting
NCT00248287 2025-01-29
CA225200
US Oncology Research
Phase 2 Active not recruiting
NCT05167409 2025-01-13
A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT04117945 2024-09-27
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT03494322 2024-05-08
EACH
University College, London
Phase 2 Active not recruiting
NCT03691714 2023-12-08
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT03391843 2018-01-05
Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer
RenJi Hospital
Phase 2 Active not recruiting